Literature DB >> 32627818

Potential of Glucagon-Like Peptide 1 as a Regulator of Impaired Cholesterol Metabolism in the Brain.

Young-Kook Kim1, Juhyun Song2.   

Abstract

Cerebral vascular diseases are the most common high-mortality diseases worldwide. Their onset and development are associated with glycemic imbalance, genetic background, alteration of atherosclerotic factors, severe inflammation, and abnormal cholesterol metabolism. Recently, the gut-brain axis has been highlighted as the key to the solution for cerebral vessel dysfunction in view of cholesterol metabolism and systemic lipid circulation. In particular, glucagon-like peptide 1 (GLP-1) is a cardinal hormone that regulates blood vessel function and cholesterol homeostasis and acts as a critical messenger between the brain and gut. GLP-1 plays a systemic regulatory role in cholesterol homeostasis and blood vessel function in various organs through blood vessels. Even though GLP-1 has potential in the treatment and prevention of cerebral vascular diseases, the importance of and relation between GLP-1 and cerebral vascular diseases are not fully understood. Herein, we review recent findings on the functions of GLP-1 in cerebral blood vessels in association with cholesterol metabolism.
Copyright © The Author(s) on behalf of the American Society for Nutrition 2020.

Entities:  

Keywords:  GLP-1; cerebral atherosclerosis; cerebral vascular disease; cholesterol metabolism; glucagon-like peptide 1

Mesh:

Substances:

Year:  2020        PMID: 32627818      PMCID: PMC7666911          DOI: 10.1093/advances/nmaa080

Source DB:  PubMed          Journal:  Adv Nutr        ISSN: 2161-8313            Impact factor:   8.701


  111 in total

1.  CNS synaptogenesis promoted by glia-derived cholesterol.

Authors:  D H Mauch; K Nägler; S Schumacher; C Göritz; E C Müller; A Otto; F W Pfrieger
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

2.  A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; M Axel Wollmer; Magdalini Tsolaki; Fabienne Brunner; Dimitra Molyva; Dieter Lütjohann; Roger M Nitsch; Christoph Hock
Journal:  J Clin Psychiatry       Date:  2005-07       Impact factor: 4.384

3.  Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans.

Authors:  Changting Xiao; Robert H J Bandsma; Satya Dash; Linda Szeto; Gary F Lewis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04-05       Impact factor: 8.311

Review 4.  Poststroke dementia.

Authors:  Didier Leys; Hilde Hénon; Marie-Anne Mackowiak-Cordoliani; Florence Pasquier
Journal:  Lancet Neurol       Date:  2005-11       Impact factor: 44.182

Review 5.  Cerebral Small Vessel Disease and Arterial Stiffness: Tsunami Effect in the Brain?

Authors:  Naoki Saji; Kenji Toba; Takashi Sakurai
Journal:  Pulse (Basel)       Date:  2016-01-20

Review 6.  Biology of incretins: GLP-1 and GIP.

Authors:  Laurie L Baggio; Daniel J Drucker
Journal:  Gastroenterology       Date:  2007-05       Impact factor: 22.682

7.  Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity.

Authors:  Ruben Nogueiras; Diego Pérez-Tilve; Christelle Veyrat-Durebex; Donald A Morgan; Luis Varela; William G Haynes; James T Patterson; Emmanuel Disse; Paul T Pfluger; Miguel López; Stephen C Woods; Richard DiMarchi; Carlos Diéguez; Kamal Rahmouni; Françoise Rohner-Jeanrenaud; Matthias H Tschöp
Journal:  J Neurosci       Date:  2009-05-06       Impact factor: 6.167

8.  Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-1984)

Authors:  E Kokmen; J P Whisnant; W M O'Fallon; C P Chu; C M Beard
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

9.  Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.

Authors:  Vaia Lambadiari; George Pavlidis; Foteini Kousathana; Maria Varoudi; Dimitrios Vlastos; Eirini Maratou; Dimitrios Georgiou; Ioanna Andreadou; John Parissis; Helen Triantafyllidi; John Lekakis; Efstathios Iliodromitis; George Dimitriadis; Ignatios Ikonomidis
Journal:  Cardiovasc Diabetol       Date:  2018-01-08       Impact factor: 9.951

10.  Genetic variants in the Fat and Obesity Associated (FTO) gene and risk of Alzheimer's disease.

Authors:  Christiane Reitz; Giuseppe Tosto; Richard Mayeux; Jose A Luchsinger
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

View more
  1 in total

1.  The Impact of Incretin-Based Medications on Lipid Metabolism.

Authors:  Habib Yaribeygi; Mina Maleki; Alexandra E Butler; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  J Diabetes Res       Date:  2021-12-29       Impact factor: 4.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.